Skip to main content
logo
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
282.99
-3.48 (-1.21%)
Mar 3, 2026, 4:00 PM EST - Market closed

Labcorp Holdings Revenue by Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
10.88B10.74B10.52B10.30B10.15B9.91B9.70B9.51B
Diagnostics Growth
7.19%8.43%8.53%8.26%7.82%5.91%5.22%4.19%
Drug Development
3.10B3.07B3.01B2.93B2.92B2.85B2.83B2.82B
Drug Development Growth
6.01%7.78%6.32%3.87%-16.80%-32.26%-42.15%-50.00%

Operating Income by Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.78B1.72B1.66B1.62B1.61B1.60B1.60B1.57B
Diagnostics Growth
10.81%7.48%3.61%3.08%0.95%-1.48%-4.68%-12.13%
Drug Development
498.50M493.20M481.90M466.00M459.00M437.20M425.30M422.50M
Drug Development Growth
8.61%12.81%13.31%10.30%2.80%-19.93%-34.34%-44.14%
General Corporate Expenses
-276.80M-276.30M-274.20M-268.70M-268.30M-269.00M-273.20M-382.10M

Operating Expense Breakdown

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.22B2.27B2.29B2.27B2.23B2.17B2.12B2.07B
Selling, General, and Administrative Growth
-0.61%4.85%7.74%9.41%5.30%2.18%0.89%-0.65%
Amortization
280.00M277.80M272.00M265.90M256.40M245.20M237.20M226.50M
Amortization Growth
9.20%13.30%14.67%17.40%8.78%3.42%-3.81%-13.38%
Restructuring and Other
127.20M27.80M39.90M47.40M46.00M52.90M42.40M46.60M-
Restructuring and Other Growth
176.52%-47.45%-5.90%1.72%-8.37%21.33%-17.19%-41.60%-
Impairments
9.60M339.80M--349.30M--349.30M349.00M285.50M276.50M274.90M------------------
Impairments Growth
-97.25%19.02%--26.33%--27.06%17.83%-38.38%-40.67%-------------------
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.